Cover Image
市場調查報告書

中樞神經系統疾病治療藥的全球市場:2016∼2020年

Global Central Nervous System Disorders Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 372088
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
中樞神經系統疾病治療藥的全球市場:2016∼2020年 Global Central Nervous System Disorders Therapeutics Market 2016-2020
出版日期: 2016年09月22日 內容資訊: 英文 147 Pages
簡介

中樞神經系統 (CNS) 疾病影響腦部和脊椎,主要的原因是感染、外傷、變性、結構缺點、腫瘤、自體免疫疾病、中風等。全球中樞神經系統疾病治療藥市場,預計2016∼2022以3.38%的年複合成長率擴大。

本報告提供全球中樞神經系統 (CNS) 疾病治療藥市場相關調查,市場現狀及成長預測,市場規模,各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 產品研發線

  • 第三階段
  • 第二階段
  • 第一階段
  • 前臨床及藥物研發

第6章 市場情況

  • 市場概要
  • 波特的五力分析

第7章 中樞神經系統疾病治療藥的全球市場:各疾病市場區隔

  • 憂鬱
  • 多發性硬化症
  • 思覺失調症
  • 雙極性疾病
  • 老年癡呆症
  • 癲癇
  • 帕金森氏症

第8章 中樞神經系統疾病治療藥的全球市場:各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第9章 中樞神經系統疾病治療藥的全球市場:促進要素

  • 特別的法律規章指定
  • 老年癡呆症,帕金森氏症,多發性硬化症的新DMD認證
  • 使用創新技術的新治療藥的開發
  • 單株抗體的高成長可能性

第10章 促進要素的影響

第11章 中樞神經系統疾病治療藥的全球市場:課題

  • 臨床實驗後期階段產品的失敗率高
  • 非侵入性神經調節及發作管理設備的使用擴大
  • 不能利用標準的診斷方法
  • 復建計劃的增加
  • 社會污名

第12章 促進要素與課題的影響

第13章 中樞神經系統疾病治療藥的全球市場:趨勢

第14章 供應商環境

  • 競爭模式
  • 主要消息
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Novartis
  • 其他值得注意的供應商

第15章 附錄

第16章 關於Technavio

目錄
Product Code: IRTNTR10192

About CNS disorders

CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

Technavio's analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Novartis

Other Prominent Vendors

  • AB Science
  • AbbVie
  • Abital Pharma
  • Acorda Therapeutics
  • Active Biotech
  • Adamas Pharmaceuticals
  • Addex Therapeutics
  • Akorn
  • Alcobra
  • Alexza Pharmaceuticals
  • Alkermes
  • Amarantus
  • Aprecia Pharmaceuticals
  • Archer Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Aurobindo Pharma
  • Auspex Pharmaceuticals
  • Avanir Pharmaceuticals
  • Biscayne Pharmaceuticals
  • Boehringer Ingelheim
  • Cerecor
  • Concordia
  • Convergence Pharmaceuticals
  • Curemark
  • CURx Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • Dart NeuroScience
  • Delpor
  • Desitin Arzneimittel
  • D-Pharm
  • Edgemont Pharmaceuticals
  • Endo International
  • E-Therapeutics
  • Euthymics
  • Evotec
  • F. Hoffmann-La Roche
  • Fabre-Kramer Pharmaceuticals
  • Forum Pharmaceuticals
  • Gedeon Richter
  • Glenmark
  • Grupo Ferrer Internacional
  • GW Pharmaceuticals
  • H. Lundbeck
  • Hisamitsu
  • Impax
  • Insero Health
  • INSYS Therapeutics
  • Intellipharmaceutics
  • Intra-Cellular Therapies
  • Ipsen
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
  • Lupin
  • MarcoPolo Pharmaceuticals
  • Marinus Pharmaceuticals
  • Meda AB
  • Merck
  • Mitsubishi Tanabe
  • MSI Methylation Sciences
  • Mylan
  • Naurex
  • Neuralstem
  • Neurelis
  • Neurovance
  • Nobelpharma
  • Noven Pharmaceuticals
  • Omeros
  • Opexa
  • Opko Health
  • Orion
  • Ophelia Pharmaceutical
  • Otsuka Pharmaceuticals
  • Palobiofarma
  • Par Pharmaceuticals
  • Pierre Fabre
  • Prana Biotechnology
  • Raptor Pharmaceutical
  • Reviva Pharmaceuticals
  • SAGE Therapeutics
  • Sanofi
  • SciFlour
  • Sedor Pharmaceuticals
  • Shire
  • Siena Biotech
  • SK Biopharmaceuticals
  • SOM Biotech
  • Somerset Pharmaceuticals
  • STADA Arzneimittel
  • Sun Pharmaceuticalc
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Suven
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals
  • Torrent Pharmaceuticals
  • Tris Pharma
  • Turing Pharmaceuticals
  • UCB
  • US WorldMeds
  • Valeant Pharmaceuticals
  • Zinfandel Pharmaceuticals
  • Zogenix

Market driver

  • New DMD approvals for AD, PD, and MS
  • For a full, detailed list, view our report

Market challenge

  • High failure rates of late-stage products in clinical trials
  • For a full, detailed list, view our report

Market trend

  • Increased uptake of new-generation drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

  • Phase III pipeline portfolio: Global CNS disorders therapeutics market
  • Phase II pipeline portfolio: Global CNS disorders therapeutics market
  • Phase I pipeline portfolio: Global CNS disorders therapeutics market
  • Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Market segmentation by type of disease

  • Global depression drugs market
  • Global MS drugs market
  • Global schizophrenia drugs market
  • Global bipolar disorder therapeutics market
  • Global AD drugs market
  • Global epilepsy drugs market
  • Global PD drugs market

PART 08: Geographical segmentation

  • CNS disorders therapeutics market in Americas
  • CNS disorders therapeutics market in EMEA
  • CNS disorders therapeutics market in APAC

PART 09: Market drivers

  • Special regulatory designations for CNS disorders
  • New DMD approvals for AD, PD, and MS
  • Development of novel therapeutics using innovative technologies
  • High growth potential of mAbs

PART 10: Impact of drivers

PART 11: Market challenges

  • High failure rates of late-stage products in clinical trials
  • Growing use of non-invasive neuromodulation and seizure management devices
  • Unavailability of standard diagnostic methods
  • Increase in rehabilitation programs
  • Social stigma associated with CNS diseases

PART 12: Impact of drivers and challenges

PART 13: Market trends

  • Popularity of me-too drugs
  • Increased uptake of new-generation drugs
  • Reformulation of marketed drugs
  • Focus on regenerative therapies for CNS disorders
  • Increase in use of LAI antipsychotics

PART 14: Vendor landscape0

  • Competitive scenario0
  • Key news3
  • GlaxoSmithKline7
  • Pfizer2
  • Eli Lilly8
  • Janssen Pharmaceuticals3
  • Novartis8
  • Other prominent vendors4

PART 15: Appendix4

  • List of abbreviations4

PART 16: Explore Technavio6

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global CNS disorders therapeutics market snapshot
  • Exhibit 03: Impact of key customer segments on market 2015
  • Exhibit 04: Key buying criteria for CNS drugs 2015
  • Exhibit 05: Share of pipeline molecules in global CNS disorders therapeutics market
  • Exhibit 06: Prevalence of dementia in various regions (millions)
  • Exhibit 07: Revenues of top-selling CNS drugs (2013-2015)
  • Exhibit 08: Global CNS disorders therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 09: Global CNS disorders therapeutics market 2015-2020 ($ billions)
  • Exhibit 10: Impact of drivers and challenges on global CNS disorders therapeutics market
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Global CNS disorders therapeutics market: Segmentation by application (2015-2020)
  • Exhibit 13: Global CNS disorders therapeutics market: Segmentation by type of disease 2015
  • Exhibit 14: Global CNS disorders therapeutics market segmentation: Growth cycle analysis
  • Exhibit 15: Global depression drugs market 2015-2020 ($ billions)
  • Exhibit 16: Opportunity analysis of global depression drugs market
  • Exhibit 17: Global MS drugs market 2015-2020 ($ billions)
  • Exhibit 18: Opportunity analysis of global MS drugs market
  • Exhibit 19: Global schizophrenia drugs market 2015-2020 ($ billions)
  • Exhibit 20: Opportunity analysis of global schizophrenia drugs market
  • Exhibit 21: Global bipolar disorder therapeutics market 2015-2020 ($ billions)
  • Exhibit 22: Opportunity analysis of global bipolar disorder therapeutics market
  • Exhibit 23: Population aged 60 years and above in millions (1950-2050)
  • Exhibit 24: Global AD drugs market 2015-2020 ($ billions)
  • Exhibit 25: Opportunity analysis of global AD drugs market
  • Exhibit 26: Global epilepsy drugs market 2015-2020 ($ billions)
  • Exhibit 27: Percentage share of marketed antiepileptic drugs based on mechanism of action
  • Exhibit 28: Opportunity analysis of global epilepsy drugs market
  • Exhibit 29: Global PD drugs market 2015-2020 ($ billions)
  • Exhibit 30: Opportunity analysis of global PD drugs market
  • Exhibit 31: Global CNS disorders therapeutics market: Geography outlook (2015-2020)
  • Exhibit 32: Global CNS disorders therapeutics market: Geography outlook 2015
  • Exhibit 33: Global CNS disorders therapeutics market segmentation by geography: Market growth lifecycle analysis 2015
  • Exhibit 34: Global CNS disorders market revenue/growth outlook in different countries/regions 2015
  • Exhibit 35: Global CNS disorders therapeutics market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 36: Opportunity analysis of CNS disorders therapeutics market in Americas
  • Exhibit 37: Projected prevalence rates of AD in Americas (2010-2050) (millions)
  • Exhibit 38: CNS disorders therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 39: Percentage share of CNS disorders therapeutics market in Americas by geography 2015
  • Exhibit 40: Opportunity analysis of CNS disorders therapeutics market in EMEA
  • Exhibit 41: CNS disorders therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 42: Opportunity analysis of CNS disorders therapeutics market in APAC
  • Exhibit 43: CNS disorders therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 44: Few of the late-stage mAbs under development for various CNS disorders
  • Exhibit 45: Impact of drivers
  • Exhibit 46: Common disorders that co-exist with bipolar disorder
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Impact of trends on global CNS disorders therapeutics market
  • Exhibit 49: Planned clinical trials of iPS cell-based therapies
  • Exhibit 50: Position of key vendors in the global CNS disorders therapeutics market 2015
  • Exhibit 51: Geographical presence of key vendors
  • Exhibit 52: Company portfolio analysis in global CNS disorders therapeutics market 2016-2020
  • Exhibit 53: GlaxoSmithKline: Profile
  • Exhibit 54: GlaxoSmithKline: Sales of top-selling CNS drugs ($ millions)
  • Exhibit 55: GlaxoSmithKline: Metrics analysis
  • Exhibit 56: GlaxoSmithKline: Growth strategy matrix
  • Exhibit 57: GlaxoSmithKline: Opportunity assessment
  • Exhibit 58: Pfizer: Profile
  • Exhibit 59: Sales of CNS drugs ($ millions)
  • Exhibit 60: Pfizer: Metrics analysis
  • Exhibit 61: Pfizer: Growth strategy matrix
  • Exhibit 62: Pfizer: Opportunity assessment
  • Exhibit 63: Eli Lilly: Profile
  • Exhibit 64: Eli Lilly: Sales of top-selling CNS drugs ($ millions)
  • Exhibit 65: Eli Lilly: Metrics analysis
  • Exhibit 66: Eli Lilly: Growth strategy matrix
  • Exhibit 67: Eli Lilly: Opportunity assessment
  • Exhibit 68: Janssen Pharmaceuticals: Profile
  • Exhibit 69: Janssen Pharmaceuticals: Sales of CNS drugs ($ millions)
  • Exhibit 70: Janssen Pharmaceuticals: Metrics analysis
  • Exhibit 71: Janssen Pharmaceuticals: Growth strategy matrix
  • Exhibit 72: Janssen Pharmaceuticals: Opportunity assessment
  • Exhibit 73: Novartis: Profile
  • Exhibit 74: Novartis: Sales of few major CNS drugs ($ millions)
  • Exhibit 75: Novartis: Metrics analysis
  • Exhibit 76: Novartis growth strategy matrix
  • Exhibit 77: Novartis: Opportunity assessment
Back to Top